First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors.

被引：2
|
作者：
Soria, J.
De Braud, F. G.
Cereda, R.
Bahleda, R.
Delmonte, A.
Angevin, E.
Varga, A.
Noberasco, C.
Dall'O, E.
Lassau, N.
Dromain, C.
Bellomi, M.
Farace, F.
Bertolini, F.
Zucchetti, M.
Marsoni, S.
Camboni, M. G.
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] European Inst Oncol, Milan, Italy
[3] EOS SpA, Milan, Italy
[4] SENDO, Milan, Italy
[5] Mario Negri Inst Pharmacol Res, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps149
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS149
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors.
    Voss, Martin Henner
    Hierro, Cinta
    Heist, Rebecca Suk
    Cleary, James M.
    Meric-Bernstam, Funda
    Gandhi, Leena
    Ishii, Nobuya
    Kirpicheva, Yulia
    Nicolas-Metral, Valerie
    Pokorska-Bocci, Anna
    Purcea, Daniela
    Vaslin, Anne
    Moulon, Corinne
    Zanna, Claudio
    Flaherty, Keith
    Tabernero, Josep
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors
    Reid, Alison H. M.
    Protheroe, Andrew
    Attard, Gerhardt
    Hayward, Nikki
    Vidal, Laura
    Spicer, James
    Shaw, Heather M.
    Bone, Elizabeth A.
    Carter, Joanne
    Hooftman, Leon
    Harris, Adrian
    De Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2009, 15 (15) : 4978 - 4985
  • [23] A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
    Jonker, D. J.
    Rosen, L. S.
    Sawyer, M. B.
    de Braud, F.
    Wilding, G.
    Sweeney, C. J.
    Jayson, G. C.
    McArthur, G. A.
    Rustin, G.
    Goss, G.
    Kantor, J.
    Velasquez, L.
    Syed, S.
    Mokliatchouk, O.
    Feltquate, D. M.
    Kollia, G.
    Nuyten, D. S. A.
    Galbraith, S.
    ANNALS OF ONCOLOGY, 2011, 22 (06) : 1413 - 1419
  • [24] First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors.
    Schram, Alison M.
    Kamath, Suneel Deepak
    El-Khoueiry, Anthony B.
    Borad, Mitesh J.
    Mody, Kabir
    Mahipal, Amit
    Goyal, Lipika
    Sahai, Vaibhav
    Schmidt-Kittler, Oleg
    Shen, Jinshan
    Jen, Kai Yu
    Deary, Alicia
    Sherwin, Cori Ann
    Padval, Mahesh
    Wolf, Beni B.
    Subbiah, Vivek
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.
    Andre, Fabrice
    Ranson, Malcolm
    Dean, Emma
    Varga, Andrea
    van der Noll, Ruud
    Stockman, Paul K.
    Ghiorghiu, Dana
    Kilgour, Elaine
    Smith, Paul D.
    Macpherson, Merran
    Lawrence, Peter
    Hastie, Andrew
    Schellens, Jan H. M.
    CANCER RESEARCH, 2013, 73 (08)
  • [26] First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.
    Hong, Yong Sang
    Lee, Jeeyun
    Han, Hye Sook
    Lee, Soo Jung
    Kim, Jin-Soo
    Ryoo, Baek-Yeol
    Lim, Hyeong-Seok
    Lee, Dae Ho
    Kim, Kyu-Pyo
    Kim, Jeong Eun
    Park, Se Hoon
    Kim, Seung Tae
    Lee, Ki Hyeong
    Choi, Moon Ki
    Han, Hyesun
    Noh, Young Su
    Kim, Yo Han
    Kang, Jahoon
    Son, Jeewoong
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors.
    Falchook, Gerald Steven
    Patel, Manish R.
    Yap, Timothy A.
    McEachern, Kristen
    Kuplast-Barr, Kristy
    Utley, Luke
    Cleary, Lisa
    Manyak, Erika
    Bozon, Viviana
    Parasuraman, Sudha
    Johnson, Melissa Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] A QTc study of cabazitaxel in patients with advanced solid tumors.
    Wade, James Lloyd
    Dakhil, Shaker R.
    Baron, Ari David
    Rottey, Sylvie
    Millard, Frederick E.
    Daugaard, Gedske
    Machiels, Jean-Pascal H.
    Conkright, William A.
    Sharma, Sunil
    Soetekouw, Patricia M. M. B.
    Yachnin, Jeffrey
    Sengelov, Lisa
    van Veldhuizen, Peter
    Agarwala, Sanjiv S.
    Nguyen, T. X. Quyen
    Chadjaa, Mustapha
    Maison-Blanche, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] First-in-man study of tafluposide, a novel inhibitor of topoisomerase I and II
    Delord, Jean-Pierre
    Bennouna, Jaafar
    Dieras, Veronique
    Campone, Mario
    Lefresne, Florence
    Aslanis, Vassili
    Douillard, Jean-Yves
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3380S - 3380S
  • [30] PHASE I STUDY OF CEDIRANIB, A VEGFR SIGNALING INHIBITOR, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Takahashi, T.
    Yamamoto, N.
    Boku, N.
    Yamazaki, K.
    Yamamoto, N.
    Yamada, Y.
    Yamada, K.
    Shin, E.
    Puchalski, T. A.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2008, 19 : 159 - 159
12345